Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01

被引：4
|
作者：
Johnson, M. L. [1 ]
Janne, P. A. [2 ]
Goto, Y. [3 ]
Yoh, K. [4 ]
Lee, S-H. [5 ,6 ]
Paz-Ares, L. [7 ]
Besse, B. [8 ]
Novello, S. [9 ]
Hayashi, H. [10 ]
Kim, D-W. [11 ,12 ]
John, T. [13 ]
Kao, S. C-H. [14 ]
Felip, E. [15 ,16 ]
Yang, J. C-H. [17 ]
Reck, M. [18 ]
Dong, Q. [19 ]
Sporchia, A. [19 ]
Sternberg, D. W. [19 ]
Yu, H. A. [20 ]
机构：
[1] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[2] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
[3] Natl Canc Ctr Hosp, Thorac Oncol Dept, Chuo Ku, Chuo City, Japan
[4] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[5] Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea
[6] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul, South Korea
[7] Univ Complutense & Ciberonc, Hosp Univ 12 Octubre, Spanish Natl Canc Res Ctr, Madrid, Spain
[8] Univ Paris Saclay, Gustave Roussy, Villejuif, France
[9] Univ Turin, San Luigi Hosp Orbassano, Dept Oncol, Orbassano, Italy
[10] Kindai Univ, Dept Med Oncol, Osaka, Japan
[11] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea
[12] Seoul Natl Univ Hosp, Seoul, South Korea
[13] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[14] Univ Sydney, Sydney Med Sch, Chris OBrien Life House, Sydney, NSW, Australia
[15] Vall dHebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain
[16] Vall dHebron Inst Oncol, Barcelona, Spain
[17] Natl Taiwan Univ Hosp, Dept Med Oncol, Taipei, Taiwan
[18] Airway Res Ctr North, German Ctr Lung Res, LungenClin, Grosshansdorf, Germany
[19] Daiichi Sankyo Inc, Oncol Clin Dev, Basking Ridge, NJ USA
[20] Mem Sloan Kettering Canc Ctr, Dept Med, Med Oncol, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2353
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1319MO
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05
    Lisberg, Aaron
    Ahn, Myung-Ju
    Kitazono, Satoru
    Cho, Byoung Chul
    Blumenschein, George R.
    Shum, Elaine
    Pons-Tostivint, Elvire
    Goto, Yasushi
    Yoh, Kiyotaka
    Paz-Ares, Luis G.
    Heist, Rebecca Suk
    Baas, Paul
    Planchard, David
    Perol, Maurice
    Felip, Enriqueta
    Su, Wu-Chou
    Zebger-Gong, Hong
    Lan, Lan
    Liu, Chelsea
    Sands, Jacob
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report
    Kim, Dong-Wan
    Kim, Sang-We
    Camidge, D. Ross
    Shu, Catherine A.
    Marrone, Kristen A.
    Le, Xiuning
    Blakely, Collin M.
    Park, Keunchil
    Chang, Gee-Chen
    Patel, Sandip Pravin
    Kar, Gozde
    Cooper, Zachary A.
    Samadani, Ramin
    Pluta, Michael
    Kumar, Rakesh
    Ramalingam, Suresh
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (05) : 650 - 656
  • [23] HERTHENA-Lung02: A Randomized Phase 3 Study of Patritumab Deruxtecan vs Platinum-Based Chemotherapy in Locally Advanced or Metastatic EGFR-Mutated NSCLC After Progression with a Third-Generation EGFR TKI
    Halmos, B.
    Yu, H.
    Wu, Y. -L.
    Nishio, M.
    Reck, M.
    Wu, E.
    Sternberg, D.
    Esker, S.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E30 - E30
  • [24] Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2
    Cho, Byoung Chul
    Wang, Yongsheng
    Felip, Enriqueta
    Cui, Jiuwei
    Spira, Alexander I.
    Neal, Joel W.
    Baik, Christina
    Marmarelis, Melina Elpi
    Ichihara, Eiki
    Lee, Jong-Seok
    Lee, Se-Hoon
    Yang, James Chih-Hsin
    Michels, Sebastian Yves Friedrich
    Anastasiou, Zacharias
    Curtin, Joshua C.
    Lyu, Xuesong
    Leconte, Isabelle
    Trani, Leonardo
    Baig, Mahadi
    Tomasini, Pascale
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Comparing subcutaneous vs intravenous amivantamab with lazertinib in EGFR-mutated advanced NSCLC: Analysis of Asian patients from PALOMA-3
    Lee, S-H.
    Akamatsu, H.
    Yang, J. C-H.
    Lim, S. M.
    Liu, B.
    John, T.
    Wang, J.
    Ohe, Y.
    Kondo, M.
    Tamiya, M.
    Danchaivijitr, P.
    Hsu, P-C.
    Zhuo, J.
    Saadoun, C.
    Saxena, N.
    Balaburski, G.
    Ribeiro, L.
    Gamil, M.
    Baig, M.
    Cheng, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1634 - S1634
  • [26] An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC).
    Raghav, Kanwal Pratap Singh
    Yoshino, Takayuki
    Taniguchi, Hiroya
    Tejpar, Sabine
    Vogel, Arndt
    Wainberg, Zev A.
    Yamaguchi, Kensei
    Kanai, Masayuki
    Liu Yali
    Mekan, Sabeen
    Pudussery, Geetha
    Qiu, Yang
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [27] HERTHENA-Lung02: A randomized Phase 3 study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR tyrosine kinase inhibitor
    Halmos, Balazs
    Yu, Helena A.
    Wu, Yi-Long
    Nishio, Makoto
    Reck, Martin
    Sternberg, David
    Esker, Stephen
    Mok, Tony
    CANCER RESEARCH, 2023, 83 (08)
  • [28] Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC
    Yu, H. A.
    Baik, C. S.
    Gold, K.
    Hayashi, H.
    Johnson, M.
    Koczywas, M.
    Murakami, H.
    Nishio, M.
    Steuer, C.
    Su, W-C.
    Yang, J.
    Karam, S.
    Qi, Z.
    Qiu, Y.
    Chen, S.
    Yu, C.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1189 - S1190
  • [29] Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2-advanced breast cancer (ABC)
    Pistilli, B.
    Pierotti, L.
    Lacroix-Triki, M.
    Vicier, C.
    Frenel, J-S.
    D'Hondt, V.
    Dalenc, F.
    Bachelot, T.
    Ducoulombier, A.
    Benderra, M-A.
    Loirat, D.
    Mayeur, D.
    Nachabeh, G. B.
    Sporchia, A.
    Suto, F.
    Michiels, S.
    Corcos, N.
    Mosele, M. F.
    Andre, F.
    Montagnac, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S357 - S357
  • [30] Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
    Ramalingam, S. S.
    O'Byrne, K.
    Boyer, M.
    Mok, T.
    Jaenne, P. A.
    Zhang, H.
    Liang, J.
    Taylor, I.
    Sbar, E. I.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 423 - 429
12345